European Palliative Care Research collaborative pain guidelines. Central side-effects management: What is the evidence to support best practice in the management of sedation, cognitive impairment and myoclonus?

Palliative Medicine

Volumn 25, Issue 5, 2011, Pages 431-441

  Stone, Patrick ^a   Minton, Ollie ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

analgesics; central nervous system stimulants; opioid

Indexed keywords

BACLOFEN; BENZODIAZEPINE DERIVATIVE; BUPIVACAINE; CAFFEINE; CARBAMAZEPINE; DANTROLENE; DEXAMPHETAMINE; DIAZEPAM; DONEPEZIL; GABAPENTIN; HALOPERIDOL; LIDOCAINE; METHYLPHENIDATE; MORPHINE; OLANZAPINE; OPIATE; PHENOBARBITAL; PHENYTOIN; PHYSOSTIGMINE; PLACEBO; QUETIAPINE; THIOPENTAL; VALPROIC ACID;

ALERTNESS; ANALGESIA; ANXIETY; CANCER PAIN; COGNITIVE DEFECT; CONFERENCE PAPER; DIZZINESS; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; EVIDENCE BASED PRACTICE; HALLUCINATION; HUMAN; HYPERALGESIA; INSOMNIA; MEDICAL PRACTICE; MEDICAL RESEARCH; META ANALYSIS; MYOCLONUS; PALLIATIVE THERAPY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; SEDATION; SIDE EFFECT; SLEEP DISORDER; SWEATING; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ANALGESICS, OPIOID; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; CONSCIOUS SEDATION; DRUG INTERACTIONS; EUROPE; HUMANS; HYPERALGESIA; METHYLPHENIDATE; MYOCLONUS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SLEEP DISORDERS;

EID: 79959700030     PISSN: 02692163     EISSN: 1477030X     Source Type: Journal    
DOI: 10.1177/0269216310380763     Document Type: Conference Paper

References (55)

1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J. 2009 ; 339: b2535 - b2535
2. Bruera E, Brenneis C, Paterson AH, MacDonald RN. Narcotics plus methylphenidate (Ritalin) for advanced cancer pain. Am J Nurs. 1988 ; 88: 1555-1556
3. Bruera E, Brenneis C, Paterson AH, MacDonald RN. Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manag. 1989 ; 4: 3-6 (Pubitemid 19093472)
4. De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain. 1991 ; 47: 337-339
5. Bruera E, Chadwick S, Brenneis C, Hanson J, MacDonald RN. Methylphenidate associated with narcotics for the treatment of cancer pain. Canc Treat Rep. 1987 ; 71: 67-70 (Pubitemid 17003435)
6. Bruera E, Fainsinger R, MacEachern T, Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain. 1992 ; 50: 75-77
7. Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain. 1992b ; 48: 163-166
8. Yee JD, Berde CB. Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J Pain Symptom Manag. 1994 ; 9: 122-125 (Pubitemid 24105186)
9. Wilwerding MB, Loprinzi CL, Mailliard JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Canc. 1995 ; 3: 135-138
10. Kreeger L, Duncan A, Cowap J. Psychostimulants used for opioid-induced drowsiness. J Pain Symptom Manag. 1996 ; 11 (1). 1-2
11. Mercadante S, Serretta R, Casuccio A. Effects of caffeine as an adjuvant to morphine in advanced cancer patients. A randomized, double-blind, placebo-controlled, crossover study. J Pain Symptom Manag. 2001 ; 21: 369-372 (Pubitemid 32452135)
12. Slatkin NE, Rhiner M, Bolton TM. Donepezil in the treatment of opioid-induced sedation: report of six cases. J Pain Symptom Manag. 2001 ; 21: 425-438 (Pubitemid 32452142)
13. Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manag. 2003 ; 26: 1049-1054 (Pubitemid 37324685)
14. Slatkin NE, Rhiner M. Treatment of opiate-related sedation: utility of the cholinesterase inhibitors. J Support Oncol. 2003 ; 1: 53-63
15. Slatkin N, Rhiner M. Treatment of opioid-induced delirium with acetylcholinesterase inhibitors: a case report. J Pain Symptom Manag. 2004 ; 27: 268-273 (Pubitemid 38317064)
16. Sylvester RK, Levitt R, Steen PD. Opioid-induced muscle activity: implications for managing chronic pain [see comment]. Ann Pharmacother. 1995 ; 29: 1118-1121
17. Cartwright PD, Hesse C, Jackson AO. Myoclonic spasms following intrathecal diamorphine. J Pain Symptom Manag. 1993 ; 8: 492-495 (Pubitemid 23292530)
18. Glavina MJ, Robertshaw R. Myoclonic spasms following intrathecal morphine. Anaesthesia. 1988 ; 43: 389-390
19. Hagen N, Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies [see comment]. J Pain Symptom Manag. 1997 ; 14: 51-58 (Pubitemid 27287412)
20. Krames ES, Gershow J, Glassberg A, et al. Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders. Cancer. 1985 ; 56: 696-702 (Pubitemid 15035603)
21. Mercadante S. Dantrolene treatment of opioid-induced myoclonus. Anesth Analg. 1995 ; 81: 1307-1308
22. Mercadante S, Villari P, Fulfaro F. Gabapentin for opioid-related myoclonus in cancer patients. Support Care Canc. 2001 ; 9: 205-206 (Pubitemid 32435812)
23. Parkinson SK, Bailey SL, Little WL, Mueller JB. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology. 1990 ; 72: 743-745 (Pubitemid 20114723)
24. Rozan JP, Kahn CH, Warfield CA. Epidural and intravenous opioid-induced neuroexcitation. Anesthesiology. 1995 ; 83: 860-863
25. Sjogren P, Jonsson T, Jensen NH, Drenck NE, Jensen TS. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain. 1993 ; 55: 93-97 (Pubitemid 23300820)
26. Passik SD, Cooper M. Complicated delirium in a cancer patient successfully treated with olanzapine. J Pain Symptom Manag. 1999 ; 17: 219-223 (Pubitemid 29135778)
27. Shinno H, Matsuoka T, Yamamoto O, et al. Successful treatment with quetiapine for delirium in terminally ill cancer patients. Psychogeriatrics. 2007 ; 7: 64-68 (Pubitemid 46887770)
28. Stillman M, Moulin D, Foley K. Paradoxical pain following high-dose spinal morphine. Pain. 1987 ; 30 (Suppl 1). S389 - S389
29. Sjogren P, Jonsson T, Jensen NH, Drenck NE, Staehelin Jensen T. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain. 1993 ; 55: 93-97 (Pubitemid 23300820)
30. Dudgeon DJ, Bruera E, Gagnon B, et al. A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients. J Pain Symptom Manag. 2007 ; 33: 365-371 (Pubitemid 46505075)
31. Mitra S. Opioid-induced hyperalgesia: pathophysiology and clinical implications. J Opioid Manag. 2008 ; 4: 123-130
32. Silverman SM. Opioid induced hyperalgesia: clinical implications for the pain practitioner. Pain Physician. 2009 ; 12: 679-684
33. Ali NM. Hyperalgesic response in a patient receiving high concentrations of spinal morphine. Anesthesiology. 1986 ; 65: 449-449
34. Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manag. 1995 ; 10: 287-291
35. Davis MP, Shaiova LA, Angst MS. When opioids cause pain [see comment]. J Clin Oncol. 2007 ; 25: 4497-4498 (Pubitemid 350013858)
36. Ito S, Liao S. Myoclonus associated with high-dose parenteral methadone. J Palliat Med. 2008 ; 11: 838-841
37. Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study [see comment]. Arch Intern Med. 2000 ; 160: 786-794 (Pubitemid 30165239)
38. MacDonald N, Der L, Allan S, Champion P. Opioid hyperexcitability: the application of alternate opioid therapy. Pain. 1993 ; 53: 353-355 (Pubitemid 23172384)
39. Mercadante S, Arcuri E. Hyperalgesia and opioid switching. Am J Hospice Palliat Med. 2005 ; 22: 291-294 (Pubitemid 41039786)
40. Mercadante S, Ferrera P, Villari P, Arcuri E. Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manag. 2003 ; 26: 769-775 (Pubitemid 36952353)
41. Mercadante S, Villari P, Ferrera P. Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manag. 2003 ; 25: 302-305 (Pubitemid 36411784)
42. Morita T, Tei Y, Inoue S. Agitated terminal delirium and association with partial opioid substitution and hydration. J Palliat Med. 2003 ; 6: 557-563 (Pubitemid 37012630)
43. Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain. 1994 ; 59: 313-316 (Pubitemid 24348916)
44. Wilson GR, Reisfield GM. Morphine hyperalgesia: a case report. Am J Hospice Palliat Med. 2003 ; 20: 459-461 (Pubitemid 39387674)
45. Vorobeychik Y, Chen L, Bush MC, Mao J. Improved opioid analgesic effect following opioid dose reduction. Pain Med. 2008 ; 9: 724-727
46. Breitbart W, Marotta R, Platt M, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of Delerium in hospitalized AIDS patients. Am J Psychiatry. 1996 ; 153: 231-237 (Pubitemid 26038965)
47. Seneff MG, Mathews RA. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother. 1995 ; 29: 690-693
48. Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med. 1997 ; 15: 335-340 (Pubitemid 27284198)
49. Olofsson SM, Weitzner MA, Valentine AD, Baile WF, Meyers CA. A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. Support Care Canc. 1996 ; 4: 351-357 (Pubitemid 126473708)
50. Akechi T, Uchitomi Y, Okamura H, et al. Usage of haloperidol for delirium in cancer patients. Support Care Cancer. 1996 ; 4: 390-392 (Pubitemid 126473714)
51. Vella-Brincat J, Macleod AD. Haloperidol in palliative care. Palliat Med. 2004 ; 18: 195-201 (Pubitemid 38771659)
52. Ripamonti C, Bruera E. CNS adverse effects of opioids in cancer patients: guidelines for treatment. CNS Drugs. 1997 ; 8: 21-37 (Pubitemid 27292545)
53. Vella-Brincat J, MacLeod AD. Adverse effects of opioids on the central nervous systems of palliative care patients. J Pain Palliat Care Pharmacother. 2007 ; 21: 15-25 (Pubitemid 46607875)
54. Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001 ; 19: 2542-2554 (Pubitemid 32391226)
55. Lawlor P. The panorama of opioid-related cognitive dysfunction in patients with cancer. Cancer. 2002 ; 94: 1836-1853 (Pubitemid 34241124)